Literature DB >> 9674697

Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents.

S Fan1, J A Wang, R Q Yuan, S Rockwell, J Andres, A Zlatapolskiy, I D Goldberg, E M Rosen.   

Abstract

Scatter factor (SF) (hepatocyte growth factor) is a cytokine that may play a role in human breast cancer invasiveness and angiogenesis. We now report that SF can block the induction of apoptosis by various DNA damaging-agents, including cytotoxic agents used in breast cancer therapy. SF protected MDA-MB-453 human breast cancer cells, EMT6 mouse mammary tumor cells and MDCK renal epithelial cells against apoptosis induced by adriamycin (ADR), X-rays, ultraviolet radiation, and other agents. Protection was observed in assays of DNA fragmentation, cell viability (MTT), and clonogenic survival. Protection of MDA-MB-453 cells against ADR was dose- and time-dependent; maximal protection required pre-incubation with 75-100 ng/ml of SF for 48 h or more. Protection required functional SF receptor (c-Met), but was not dependent on p53. Western blotting analysis revealed that pre-treatment of MDA-MB-453 cells with SF inhibited the ADR-induced decreases in the levels of Bcl-XL, an anti-apoptotic protein related to Bcl-2; and the dose-response and time course characteristics for SF-mediated increases in the Bcl-XL protein levels of ADR-treated cells were consistent with the degrees of protection against apoptosis observed under the same conditions. Furthermore, Bcl-XL levels were not down-regulated by ADR in MDA-MB-231 breast cancer cells, consistent with the finding that SF failed to protect these cells against ADR, despite the fact that they contain functional c-Met receptor. In contrast to Bcl-XL, SF blocked ADR-induced increases in c-Myc and inhibited the expression of p21WAF1/CIP1 and of the BRCA1 protein in MDA-MB-453 cells. However, SF did not cause significant changes in the cell cycle distribution of ADR-treated cells. These findings suggest that SF-mediated protection of human breast cancer cells may involve inhibition of one or more pathways required for the activation of apoptosis and may particularly target the anti-apoptotic mitochondrial membrane pore-forming protein Bcl-XL as a component of the protective mechanism. By implication, the accumulation of SF within human breast cancers may contribute to the development of a radio- or chemoresistant phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674697     DOI: 10.1038/sj.onc.1201943

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells.

Authors:  A Danilkovitch; S Donley; A Skeel; E J Leonard
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair.

Authors:  S Fan; Y X Ma; M Gao; R Q Yuan; Q Meng; I D Goldberg; E M Rosen
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Authors:  Kanwal P Raghav; Wenting Wang; Shuying Liu; Mariana Chavez-MacGregor; Xiaolong Meng; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; George R Blumenschein; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

4.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.

Authors:  B Cao; Y Su; M Oskarsson; P Zhao; E J Kort; R J Fisher; L M Wang; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 5.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

Review 6.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

7.  Role of Bcl-xL induction in HGF-mediated renal epithelial cell survival after oxidant stress.

Authors:  Jinglan Zhang; Junwei Yang; Youhua Liu
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 8.  Targeting the Met signaling pathway in renal cancer.

Authors:  Alessio Giubellino; W Marston Linehan; Donald P Bottaro
Journal:  Expert Rev Anticancer Ther       Date:  2009-06       Impact factor: 4.512

9.  Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells.

Authors:  Mathieu Provençal; Nancy Berger-Thibault; David Labbé; Ryan Veitch; Dominique Boivin; Georges-Etienne Rivard; Denis Gingras; Richard Béliveau
Journal:  J Neurooncol       Date:  2009-11-18       Impact factor: 4.130

10.  The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival.

Authors:  James Y Dai; Marie C DeFrances; Chunbin Zou; Carla J Johnson; Reza Zarnegar
Journal:  J Cell Biochem       Date:  2009-08-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.